December 7, 2017
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the Centers for Medicare and Medicaid Services’ (CMS) latest National Health Expenditure data:
“This report shows that even in the midst of rising drug prices PBMs are continuing to keep overall spending and out-of-pocket costs down.
Since one way plans reduce costs is by negotiating aggressive rebates and discounts from drug companies and drugstores, CMS should avoid new requirements on point-of-sale rebates or preferred pharmacy networks that make it harder for Part D plans to get these price concessions.
As CMS notes, requiring plans to estimate and apply manufacturer rebates at the point-of-sale would raise premiums by up to $28 billion and taxpayer costs by up to $82 billion over the next decade.”